AU2016219161A1 - Inhibition of Yap for breaking tumor immune tolerance - Google Patents

Inhibition of Yap for breaking tumor immune tolerance Download PDF

Info

Publication number
AU2016219161A1
AU2016219161A1 AU2016219161A AU2016219161A AU2016219161A1 AU 2016219161 A1 AU2016219161 A1 AU 2016219161A1 AU 2016219161 A AU2016219161 A AU 2016219161A AU 2016219161 A AU2016219161 A AU 2016219161A AU 2016219161 A1 AU2016219161 A1 AU 2016219161A1
Authority
AU
Australia
Prior art keywords
yap
cells
cancer
cell
gvax
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016219161A
Other languages
English (en)
Inventor
Joseph Barbi
Duojia Pan
Fan Pan
Drew M. Pardoll
Benjamin Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of AU2016219161A1 publication Critical patent/AU2016219161A1/en
Priority to AU2021203851A priority Critical patent/AU2021203851B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2016219161A 2015-02-12 2016-02-12 Inhibition of Yap for breaking tumor immune tolerance Abandoned AU2016219161A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021203851A AU2021203851B2 (en) 2015-02-12 2021-06-10 Inhibition of YAP for breaking tumor immune tolerance

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562115414P 2015-02-12 2015-02-12
US62/115,414 2015-02-12
PCT/US2016/017697 WO2016130889A1 (en) 2015-02-12 2016-02-12 Inhibition of yap for breaking tumor immune tolerance

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021203851A Division AU2021203851B2 (en) 2015-02-12 2021-06-10 Inhibition of YAP for breaking tumor immune tolerance

Publications (1)

Publication Number Publication Date
AU2016219161A1 true AU2016219161A1 (en) 2017-08-31

Family

ID=56615092

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016219161A Abandoned AU2016219161A1 (en) 2015-02-12 2016-02-12 Inhibition of Yap for breaking tumor immune tolerance
AU2021203851A Active AU2021203851B2 (en) 2015-02-12 2021-06-10 Inhibition of YAP for breaking tumor immune tolerance

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021203851A Active AU2021203851B2 (en) 2015-02-12 2021-06-10 Inhibition of YAP for breaking tumor immune tolerance

Country Status (7)

Country Link
US (1) US11491139B2 (enExample)
EP (1) EP3256123B1 (enExample)
JP (3) JP2018505223A (enExample)
CN (1) CN107635582B (enExample)
AU (2) AU2016219161A1 (enExample)
CA (1) CA2976377A1 (enExample)
WO (1) WO2016130889A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170085619A (ko) * 2016-01-14 2017-07-25 연세대학교 산학협력단 Alk 저해제에 대한 내성을 획득한 eml4-alk 양성 비소세포폐암의 치료를 위한 스타틴계 약물의 용도
US10925869B2 (en) 2016-05-26 2021-02-23 University of Pittsburgh—of the Commonwealth System of Higher Education Compositions and methods for treating pulmonary vascular disease
WO2018085275A1 (en) * 2016-11-02 2018-05-11 The Regents Of The University Of California Targeting lats1/2 and the hippo intracellular signaling pathway for cancer immunotherapy
JP6886278B2 (ja) * 2016-12-01 2021-06-16 学校法人慶應義塾 抗癌剤
WO2018119418A1 (en) * 2016-12-24 2018-06-28 Nivien Therapeutics Company Methods relating to the treatment of chemoresistant and immuno-resistant cancer
EP3568150A4 (en) * 2017-01-10 2020-12-02 Xcella Biosciences, Inc. POLYTHERAPY FOR TUMOR TREATMENT WITH INTEGRIN-BOUND FC FUSION PROTEIN AND IMMUNE MODULATOR
EP3713569B1 (en) * 2017-11-22 2024-03-13 University of Pittsburgh- Of the Commonwealth System of Higher Education Therapeutic particle comprising a yap1/wwrt1 inhibiting agent and the glutaminase inhibiting agent 2-cyclopropyl-n-[5-(4-{ [5-(2-phenylacetamido)-1,3,4-thiadiazol-2-yl]amino}piperidin-1-yl)-1,3,4-thiadiazol-2-yl] acetamide and use thereof for treating a pulmonary disease
US11360080B2 (en) * 2018-08-17 2022-06-14 National Health Research Institutes AhR-ROR-γt complex as a biomarker and therapeutic target for autoimmune disease and IL-17A-associated disease
TW202214854A (zh) * 2019-01-31 2022-04-16 美商Ionis製藥公司 Yap1表現之調節劑
WO2020214650A1 (en) * 2019-04-15 2020-10-22 Trustees Of Boston University Methods and compositions for modulating the immune system
US20210338265A1 (en) * 2020-04-30 2021-11-04 Ethicon, Inc. Methods and devices for delivering cancer therapy to a target tissue site via a cored tissue cavity
JP7514508B2 (ja) * 2020-05-19 2024-07-11 国立大学法人鳥取大学 胆道がん治療薬
US12653785B2 (en) 2020-05-21 2026-06-16 University of Pittsburgh—of the Commonwealth System of Higher Education Compositions and methods for administering a YAP1/WWRT1 inhibiting composition and a GLS1 inhibiting composition
AU2021372270A1 (en) * 2020-10-28 2023-06-22 Baylor College Of Medicine Targeting of src-3 in immune cells as an immunomodulatory therapeutic for the treatment of cancer
CN113456633A (zh) * 2021-06-11 2021-10-01 广西医科大学 红海海绵素a在制备抗肺癌侵袭转移药物中的应用
CN118105483B (zh) * 2024-02-02 2025-03-11 济宁医学院附属医院 Ox40激活抗体和抗血管生成剂在制备抗肿瘤药物中的应用
WO2026071140A1 (ja) * 2024-09-30 2026-04-02 日東電工株式会社 Ｙａｐ１阻害剤およびｗｗｔｒ１阻害剤の両方に対する対象の応答のモニタリング方法、層別化方法およびそれらの補助方法、ならびにｐｃｓｋ９発現阻害剤およびｐｃｓｋ９関連疾患の治療または予防用組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0605685D0 (en) * 2006-03-21 2006-05-03 Lytix Biopharma As Inhibition of tumour growth
DE60334303D1 (de) * 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
US20040110731A1 (en) * 2002-12-04 2004-06-10 Chan Agnes H. Photodynamic therapy for the treatment of non-melanoma skin cancer
JP2010504356A (ja) * 2006-09-20 2010-02-12 ザ ジョンズ ホプキンス ユニバーシティー 抗ｂ７−ｈ１抗体を用いた癌及び感染性疾患の組合せ療法
KR101050829B1 (ko) * 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
WO2011017809A1 (en) * 2009-08-11 2011-02-17 The University Of British Columbia Autophagy inhibitor compounds, compositions and methods for the use thereof in the treatment of cancer
US20150157584A1 (en) * 2012-06-11 2015-06-11 The J. David Gladstone Institutes Inhibitors of hippo-yap signaling pathway

Also Published As

Publication number Publication date
US20180021306A1 (en) 2018-01-25
JP2022136162A (ja) 2022-09-15
JP2020164539A (ja) 2020-10-08
JP7509830B2 (ja) 2024-07-02
JP7186196B2 (ja) 2022-12-08
AU2021203851A1 (en) 2021-07-22
WO2016130889A1 (en) 2016-08-18
EP3256123B1 (en) 2023-06-07
JP2018505223A (ja) 2018-02-22
CN107635582A (zh) 2018-01-26
CN107635582B (zh) 2022-08-02
US11491139B2 (en) 2022-11-08
EP3256123A4 (en) 2019-02-13
CA2976377A1 (en) 2016-08-18
AU2021203851B2 (en) 2023-08-31
EP3256123A1 (en) 2017-12-20

Similar Documents

Publication Publication Date Title
AU2021203851B2 (en) Inhibition of YAP for breaking tumor immune tolerance
US12312398B2 (en) Compositions and methods for targeting activin signaling to treat cancer
EP3213765A2 (en) Antigen-specific t cell receptors and t cell epitopes
US20240182543A1 (en) Engineered chimeric fusion protein compositions and methods of use thereof
WO2020146345A1 (en) Methods of treating cancer using lsd1 inhibitors and/or tgf-beta inhibitors in combination with immunotherapy
CA3023845A1 (en) Immune checkpoint inhibitors and cytotoxic t cells for the treatment of cancer
US20250276064A1 (en) Engineered chimeric fusion protein compositions and methods of use thereof
WO2020232510A1 (en) Method of treatment
US12158399B2 (en) CaMKK2 inhibitor compositions and methods of using the same
US20230416746A1 (en) Immuno-oncology targets to improve t-cell metabolic response
US20250154266A1 (en) Activin signaling activity
CA3190792A1 (en) Methods and compositions for pancreatic cancer evaluation and treatment
KR20220092905A (ko) 입양 면역요법
US20250144107A1 (en) Use of a pikfyve inhibitor in combination with immunotherapy
CN120265755A (zh) 用于疾病治疗的t细胞-nk细胞相互作用抑制剂

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted